Ipsen Boosts Rare Disease Portfolio with Blueprint’s BLU-782

By Pratika Pahwa

Pharma Deals Review: Vol 2019 Issue 10 (Table of Contents)

Published: 26 Oct-2019

DOI: 10.3833/pdr.v2019.i10.2467     ISSN: 1756-7874

Section: Licensing



In a quest to expand its rare disease pipeline, Clementia, a subsidiary of Ipsen, has entered into an agreement with Blueprint Medicines for up to US$535 M to develop BLU-782, an investigational ALK2 inhibitor for the treatment of fibrodysplasia ossificans progressiva (FOP)...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details